about
Absolute quantification of human uridine-diphosphate glucuronosyl transferase (UGT) enzyme isoforms 1A1 and 1A6 by tandem LC-MS.Extreme low dose of 5-fluorouracil reverses MDR in cancer by sensitizing cancer associated fibroblasts and down-regulating P-gpCombinational delivery of hydrophobic and hydrophilic anticancer drugs in single nanoemulsions to treat MDR in cancerPulmonary immunization of guinea pigs with diphtheria CRM-197 antigen as nanoparticle aggregate dry powders enhance local and systemic immune responses.Characterization of biomolecular nanoconjugates by high-throughput delivery and spectroscopic difference.Disulfide bond bridge insertion turns hydrophobic anticancer prodrugs into self-assembled nanomedicinesQuantitative profiling of human renal UDP-glucuronosyltransferases and glucuronidation activity: a comparison of normal and tumoral kidney tissuesQuantification of human uridine-diphosphate glucuronosyl transferase 1A isoforms in liver, intestine, and kidney using nanobore liquid chromatography-tandem mass spectrometry.Programmed Hydrolysis in Designing Paclitaxel Prodrug for Nanocarrier Assembly.Multiplexed Targeted Quantitative Proteomics Predicts Hepatic Glucuronidation Potential.New mouse xenograft model modulated by tumor-associated fibroblasts for human multi-drug resistance in cancer.UGT concentrations in human rectal tissue after multidose, oral curcuminScaling factors for the in vitro-in vivo extrapolation (IV-IVE) of renal drug and xenobiotic glucuronidation clearanceTargeted precise quantification of 12 human recombinant uridine-diphosphate glucuronosyl transferase 1A and 2B isoforms using nano-ultra-high-performance liquid chromatography/tandem mass spectrometry with selected reaction monitoringQuantitative Characterization of Major Hepatic UDP-Glucuronosyltransferase (UGT) Enzymes in Human Liver Microsomes: Comparison of Two Proteomic Methods and Correlation with Catalytic Activity.Multimodal analysis of drug transporter expression in gastrointestinal tissue.The Effect of Surfactant on Paclitaxel Nanocrystals: An In Vitro and In Vivo Study.Theranostic nanoemulsions: codelivery of hydrophobic drug and hydrophilic imaging probe for cancer therapy and imaging.Immunization of guinea pigs with novel hepatitis B antigen as nanoparticle aggregate powders administered by the pulmonary routePharmacokinetics of sequential doses of capreomycin powder for inhalation in guinea pigsTargeted quantitative proteomics for the analysis of 14 UGT1As and -2Bs in human liver using NanoUPLC-MS/MS with selected reaction monitoring.Arginine vasopressin release in response to the administration of 3,4-methylenedioxymethamphetamine ("ecstasy"): is metabolism a contributory factor?Action of MDMA (ecstasy) and its metabolites on arginine vasopressin release.Candida albicans in urine can produce testosterone: impact on the testosterone/epitestosterone sports drug test.Effects of direct spiking of silicone oil into a model pMDI formulation.Utility of Oatp1a/1b-knockout and OATP1B1/3-humanized mice in the study of OATP-mediated pharmacokinetics and tissue distribution: case studies with pravastatin, atorvastatin, simvastatin, and carboxydichlorofluorescein.Quantification of Four Efflux Drug Transporters in Liver and Kidney Across Species Using Targeted Quantitative Proteomics by Isotope Dilution NanoLC-MS/MS.Efflux transporter breast cancer resistance protein dominantly expresses on the membrane of red blood cells, hinders partitioning of its substrates into the cells, and alters drug-drug interaction profiles.Low-dose MDMA ("ecstasy") induces vasopressin secretion.Quantification of membrane transporter proteins in human lung and immortalized cell lines using targeted quantitative proteomic analysis by isotope dilution nanoLC-MS/MS.A monolayer of primary colonic epithelium generated on a scaffold with a gradient of stiffness for drug transport studiesMolecular transport through primary human small intestinal monolayers by culture on a collagen scaffold with a gradient of chemical cross-linkingEvaluation of human primary intestinal monolayers for drug metabolizing capabilitiesPharmacokinetics of Organic Cation Transporter 1 (OCT1) Substrates in Oct1/2 Knockout Mice and Species Difference in Hepatic OCT1-Mediated UptakeFactors Affecting Interindividual Variability of Hepatic UGT2B17 Protein Expression Examined Using a Novel Specific Monoclonal AntibodyTargeted quantitative proteomic analysis of drug metabolizing enzymes and transporters by nano LC-MS/MS in the sandwich cultured human hepatocyte modelAntiretroviral Drug Concentrations in Lymph Nodes: A Cross-Species Comparison of the Effect of Drug Transporter Expression, Viral Infection, and Sex in Humanized Mice, Nonhuman Primates, and Humans
P50
Q33428295-3492758A-DD4E-4D56-A1DA-D3197729FD71Q33853293-A15DA23B-74DF-45A8-8BC1-FB16F96B90C1Q34089249-DB3365B9-ED97-47E1-A08C-2CD2083ADE3EQ34293599-A60E20FC-AC31-4955-90D8-02406A06900DQ34971975-3AE1F2BC-206D-4DB1-86AA-2DC7043ADFBAQ35100603-4315EB84-DA08-4421-881F-9C226236A0A5Q35197861-65516497-9D66-43CA-A5E5-8F7174FB47B9Q35675171-A6326251-193F-4350-B0B2-900090F2B408Q35844437-2762E4DE-369D-45E9-91D8-58CCE5A2DF34Q35962005-5D307DC4-5BBC-4E01-87FC-80C4EAC71837Q36094989-6352406A-C5F1-45E1-AFD7-52D339E632C3Q36719646-01D4D947-E3C3-4BDC-9888-C7C6F9624F99Q36924729-A37049D2-9624-490B-A064-F20BE2A4B7D0Q37325602-8C40596C-8806-403F-B211-04A652678EECQ38646093-32927F77-3D5F-411D-863B-BE6F8C03AC5AQ38738700-1770E652-1884-4012-AC39-301FDC21926EQ38764495-14851A8A-9840-4000-A26B-96F396CC3F59Q38977484-CDC45EC3-65AB-4133-81B5-9BC29251733AQ41950285-0204E5D1-9147-470C-AC2F-C61CD22951CAQ42151625-BB8C2D22-C38F-47C2-9926-4F5AB124E20EQ43735205-F6753B16-D362-4668-877B-8630713EF328Q43791430-87DB2ECA-EF4B-470D-9848-5560DAD0FF5BQ44053646-412358EF-2DBC-4821-9B87-90B072B9E4D6Q44153141-50ECFF9D-6187-4495-90D1-DB17E352BDA5Q44633073-A732D63E-D358-400C-9F19-AD864BE865E1Q44709339-78C8DB84-8C2D-4A36-B6D1-0227E5DD6A87Q46525620-EB626EB0-69B4-43AD-84A8-35B04EB95C06Q47446009-3547CE00-66EE-4143-99DA-04C795D3F40FQ47943432-830C6DBC-C59E-41CB-93AB-B68E301C9909Q52726352-7DF4F21F-B97E-4D8E-8C53-339343BCAB09Q57814037-3DEFA6E4-F08D-44F6-9F9E-BCBEED724D6CQ64083816-F15B7D46-3845-4D8A-B28E-5D749795CD7DQ91218601-7D66B835-CA20-41A6-986C-D9060FDE03A7Q91472401-5A89D582-A274-4249-9402-072B158365D2Q92021774-10C735FE-EE36-497E-96BE-F006C4E5DAB1Q92489574-D92C0D09-FE9C-47E2-A365-1332232E96BBQ92998366-EBF22EA2-FC63-4FE5-B860-0892051A55CD
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
John Kevin Fallon
@ast
John Kevin Fallon
@en
John Kevin Fallon
@es
John Kevin Fallon
@sl
type
label
John Kevin Fallon
@ast
John Kevin Fallon
@en
John Kevin Fallon
@es
John Kevin Fallon
@sl
prefLabel
John Kevin Fallon
@ast
John Kevin Fallon
@en
John Kevin Fallon
@es
John Kevin Fallon
@sl
P106
P21
P31
P496
0000-0003-1848-0121